Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 1.95B +80.0% |
| Revenue (ttm) | n/a |
| Net Income | -151.78M |
| EPS | -2.02 |
| Shares Out | 82.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,182,879 |
| Open | 24.80 |
| Previous Close | 25.05 |
| Day's Range | 23.34 - 25.09 |
| 52-Week Range | 12.59 - 47.65 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 48.50 (+104.73%) |
| Earnings Date | May 6, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 104.73% from the latest price.
News
Mineralys Therapeutics falls -17.1%
Mineralys Therapeutics (MLYS) is down -17.1%, or -$4.93 to $23.92.
Mineralys Therapeutics falls -12.7%
Mineralys Therapeutics (MLYS) is down -12.7%, or -$3.67 to $25.18.
Mineralys prices offering of 5.66M shares of common stock at $26.50
Mineralys Therapeutics (MLYS) announced the pricing of an underwritten offering of 5.66M shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys…
Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Significant financial transactions have fully funded commercialization plans for lorundrostat, a selective aldosterone synthase inhibitor targeting uncontrolled and resistant hypertension. Clinical trials show robust efficacy and safety, with strong physician interest and a large addressable market of 20 million U.S. patients.
Mineralys to repurchase future royalty payments in Tanabe license agreement
Mineralys Therapeutics (MLYS) announced the repurchase of all potential future royalty payments due to Tanabe Pharma Corporation related to lorundrostat in exchange for a $200M upfront payment and up ...
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –
Mineralys Therapeutics presents new data for lorundrostat
Mineralys Therapeutics (MLYS) presented new clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection in Gdansk, Poland. The analysis evaluated the effi...
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented at a major European medical conference on Satur...
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities ...
Mineralys Therapeutics Transcript: AGM 2026
Shareholders convened to vote on director elections and auditor ratification, with a quorum present. Voting results will be disclosed in a Form 8-K within four business days.
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –
Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Lorundrostat’s NDA was accepted in Q1, with robust clinical data supporting its use in resistant hypertension. Launch preparations are underway, focusing on key prescribers and payer engagement, while international commercialization will rely on partnerships. Cash reserves support operations into 2028.
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $49 and keeps a Buy rating on the shares.
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
“We continue to make strong progress advancing lorundrostat toward potential approval, moving closer towards our goal of delivering what we believe has the potential to be a best-in-class aldosterone ...
Mineralys Therapeutics Earnings Call Transcript: Q1 2026
FDA accepted the NDA for lorundrostat, supported by robust clinical data, with a PDUFA date set for December 2026. Cash reserves remain strong, and operational focus is on commercial launch readiness and strategic partnerships. Significant market opportunity exists in resistant hypertension.
Mineralys Therapeutics Earnings release: Q1 2026
Mineralys Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Mineralys Therapeutics Quarterly report: Q1 2026
Mineralys Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Mineralys Therapeutics Slides: Corporate presentation
Mineralys Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities ...
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities ...
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Mineralys Therapeutics (MLYS) with a Buy rating and no price target The company’s lorundrostat has broad, blockbuster potential in uncontrolled and resistant hypertensio...